title: A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II.
abstract: ALS is a progressive motor neuron disease with no effective treatment. The anti-excitotoxic drug riluzole (100 mg/day) has been shown to decrease mortality and muscular deterioration in ALS patients. To confirm and extend the therapeutic effect of riluzole, we performed a double-blind, placebo-controlled, multicenter, international, dose-ranging (50, 100, 200 mg/day), stratified study in 959 ALS outpatients treated for up to 18 months. Primary efficacy criterion was survival and the effect of treatment was analyzed before (Wilcoxon and log rank tests) and after adjustment on prognostic factors (Cox model). Secondary efficacy criterion was disease progression assessed through change in functional measures. Tracheostomy-free survival rates were: 50.4% (placebo), 55.3% (50 mg riluzole) (p = 0.23, Wilcoxon test; p = 0.25, log-rank test), 56.8% (100 mg riluzole) (p = 0.05, Wilcoxon test; p = 0.076, log-rank test), and 57.8% (200 mg riluzole) (p = 0.061, Wilcoxon test; p = 0.075, log-rank test). At the end of the 18-month study, there was a significant dose-related decrease in risk of death or tracheostomy (p = 0.04). Adjustment for baseline prognostic factors showed a 35% decreased risk of death with the 100-mg dose compared with placebo (p = 0.002). No significant treatment effects were detected for the functional assessments. The most frequent dose-related adverse events included nausea, asthenia, and elevated liver enzyme levels. This study confirms the therapeutic effect of riluzole in a large representative ALS sample, over an 18-month period. Riluzole is well tolerated and decreases the risk of death or tracheostomy in ALS patients.
authors.affiliation: Department of Pharmacology, Hôpital de la Pitié-Salpêtrière, Paris, France.
authors.forename: L
authors.initials: L
authors.lastname: Lacomblez
authors.forename: G
authors.initials: G
authors.lastname: Bensimon
authors.forename: P N
authors.initials: PN
authors.lastname: Leigh
authors.forename: P
authors.initials: P
authors.lastname: Guillet
authors.forename: L
authors.initials: L
authors.lastname: Powe
authors.forename: S
authors.initials: S
authors.lastname: Durrleman
authors.forename: J C
authors.initials: JC
authors.lastname: Delumeau
authors.forename: V
authors.initials: V
authors.lastname: Meininger
mesh_terms: D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D019782:Riluzole; D016019:Survival Analysis; D013844:Thiazoles / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D018691:Excitatory Amino Acid Antagonists; D013844:Thiazoles; D019782:Riluzole